 |
|
Vyvanse CII significantly improved ADHD symptoms for children 13 hours after administration
July 23, 2009Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration. In this pediatric analog classroom study, treatment with Vyvanse was associated with significant improvement in behavior and attention in children at each time point measured, with improvement at 13 hours after administration.
"Pediatric patients may require ADHD symptom improvement both at school and after school," said Sharon Wigal, PhD, lead investigator of the study, clinical professor of pediatrics and director of clinical trials in the Child Development Center at the University of California, Irvine. "These published data are the first to have shown duration of effect of an oral ADHD stimulant in children aged 6 to 12 at 13 hours after administration. Physicians and caregivers who are seeking a long-acting medication that provides ADHD symptom improvement from morning through homework and family time may want to consider this Vyvanse study data."
On May 22, 2009, the US Food and Drug Administration (FDA) approved a change to the prescribing information for Vyvanse to include supplemental data that demonstrated significant ADHD symptom improvement in children aged 6 to 12 from the first time point measured (1.5 hours) up to 13 hours postdose. Vyvanse is now the first and only oral ADHD stimulant treatment to have efficacy at 13 hours after administration for pediatric patients included in its product labeling.
"Shire is proud to be at the forefront of ADHD research and treatment development and is committed to providing patients with effective ADHD medications, such as Vyvanse," said Liza Squires, MD, Research and Development Business Unit Leader for Shire. "These findings provided further support that Vyvanse can be an important treatment option for children who require duration of ADHD symptom improvement throughout the day."
Vyvanse Demonstrated Significant Symptom Improvement at 13 Hours After Administration
The study was a randomized, double-blind, placebo-controlled, analog classroom study that assessed the efficacy and safety of Vyvanse in 129 children aged 6 to 12 years with ADHD. Following a four-week, open-label, dose-optimization phase with Vyvanse at 30 mg, 50 mg, and 70 mg doses, patients entered a two-week, double-blind, crossover phase where they were randomized into two groups. One group received their optimal dose of Vyvanse the first week and placebo the second week. The second group received placebo the first week and their optimal dose of Vyvanse the second week.
The primary objective of this study was to assess the time of onset of Vyvanse compared with placebo, as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment (SKAMP-D) rating scale. Secondary objectives included assessment of the duration of efficacy of VYVANSE compared with placebo, as measured by the SKAMP-D scale, and assessment of efficacy and time of onset of Vyvanse compared with placebo as measured by SKAMP Attention (SKAMP-A), and Permanent Product Measure of Performance (PERMP) scales.
In the study, Vyvanse demonstrated significant efficacy versus placebo at 1.5 hours, the first time point measured. Further, Vyvanse treatment was associated with significant efficacy as measured by both subjective (SKAMP-D and SKAMP-A) and objective (PERMP) assessments from the first time point (1.5 hours) through the last time point (13 hours) assessed during the classroom day, and at all time points in between (2.5, 5.0, 7.5, 10.0, and 12.0 hours).
Safety was also evaluated during the study. The adverse event profile for Vyvanse was similar to other currently marketed stimulants. The most frequently reported adverse events (greater than or equal to 10 percent) in the dose-optimization phase for patients taking Vyvanse were decreased appetite, insomnia, headache, irritability, upper abdominal pain, and affect lability.
Vyvanse, which was introduced in the United States in July 2007 for the treatment of ADHD in children aged 6 to 12 years and approved in April 2008 to treat ADHD in adults, is currently available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. To date, more than 6 million Vyvanse prescriptions have been filled, bringing the current US market share to over 12 percent based on weekly branded prescription volume. Additionally, Shire has executed agreements with 10 of Shire's top 11 managed care organizations (MCOs) to cover Vyvanse in a preferred formulary position.
Vyvanse is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of Vyvanse to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times.
Porter Novelli
"Shire is proud to be at the forefront of ADHD research and treatment development and is committed to providing patients with effective ADHD medications, such as Vyvanse," said Liza Squires, MD, Research and Development Business Unit Leader for Shire. "These findings provided further support that Vyvanse can be an important treatment option for children who require duration of ADHD symptom improvement throughout the day."
Vyvanse Demonstrated Significant Symptom Improvement at 13 Hours After Administration
The study was a randomized, double-blind, placebo-controlled, analog classroom study that assessed the efficacy and safety of Vyvanse in 129 children aged 6 to 12 years with ADHD. Following a four-week, open-label, dose-optimization phase with Vyvanse at 30 mg, 50 mg, and 70 mg doses, patients entered a two-week, double-blind, crossover phase where they were randomized into two groups. One group received their optimal dose of Vyvanse the first week and placebo the second week. The second group received placebo the first week and their optimal dose of Vyvanse the second week.
The primary objective of this study was to assess the time of onset of Vyvanse compared with placebo, as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham Deportment (SKAMP-D) rating scale. Secondary objectives included assessment of the duration of efficacy of VYVANSE compared with placebo, as measured by the SKAMP-D scale, and assessment of efficacy and time of onset of Vyvanse compared with placebo as measured by SKAMP Attention (SKAMP-A), and Permanent Product Measure of Performance (PERMP) scales.
In the study, Vyvanse demonstrated significant efficacy versus placebo at 1.5 hours, the first time point measured. Further, Vyvanse treatment was associated with significant efficacy as measured by both subjective (SKAMP-D and SKAMP-A) and objective (PERMP) assessments from the first time point (1.5 hours) through the last time point (13 hours) assessed during the classroom day, and at all time points in between (2.5, 5.0, 7.5, 10.0, and 12.0 hours).
Safety was also evaluated during the study. The adverse event profile for Vyvanse was similar to other currently marketed stimulants. The most frequently reported adverse events (greater than or equal to 10 percent) in the dose-optimization phase for patients taking Vyvanse were decreased appetite, insomnia, headache, irritability, upper abdominal pain, and affect lability.
Vyvanse, which was introduced in the United States in July 2007 for the treatment of ADHD in children aged 6 to 12 years and approved in April 2008 to treat ADHD in adults, is currently available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. To date, more than 6 million Vyvanse prescriptions have been filled, bringing the current US market share to over 12 percent based on weekly branded prescription volume. Additionally, Shire has executed agreements with 10 of Shire's top 11 managed care organizations (MCOs) to cover Vyvanse in a preferred formulary position.
Vyvanse is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of Vyvanse to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times.
Porter Novelli
ADHD Current Events and ADHD News RSSCommon plastics chemicals linked to ADHD symptoms
Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items.
Pivotal study for PSD502 -- the first potential treatment for premature ejaculation
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
Teens' mental health affects how long they stay in school, new study shows
Queen's University researcher Steven Lehrer has won a prestigious international award in recognition of his contributions to health economics.
Faulty body clock may make kids bipolar
Malfunctioning circadian clock genes may be responsible for bipolar disorder in children. Researchers writing in the open access journal BMC Psychiatry found four versions of the regulatory gene RORB that were associated with pediatric bipolar disorder.
Language support is important for children with autism
Teachers and parents must be vigilant in observing difficulties with language comprehension, reading and spelling in children and young people with autism, Asperger's syndrome and ADHD.
Experts unveil new CVD guidelines and position papers
Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.
Eating liquorice in pregnancy may affect a child's IQ and behavior
Expectant mothers who eat excessive quantities of liquorice during pregnancy could adversely affect their child's intelligence and behaviour, a study has shown.
Are the monoamines involved in shaping conduct disorders?
Antisocial and aggressive behaviours represent a widespread and expensive social problem. Recent research has convincingly shown that there is a strong interaction between genetic inheritance and environment for development of personality and behaviour.
ADHD genes found, known to play roles in neurodevelopment
Pediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD.
Measuring intellectual disability
Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome.
More ADHD Current Events and ADHD News Articles
 |
The Survival Guide for Kids with ADD or ADHD by John F. Taylor Ph.D. (Author) What are ADD and ADHD? What does it mean to have ADD and ADHD? How can kids diagnosed with ADD and ADHD help themselves succeed in school, get along better at home, and form healthy, enjoyable relationships with peers? In kid-friendly language and a format that welcomes reluctant and easily distracted readers, Free Spirit's newest survival guide helps kids know they're not alone and offers practical strategies for taking care of oneself, modifying behavior, enjoying school, having fun, and dealing (when needed) with doctors, counselors, and medication. Includes real-life scenarios, quizzes, and a special message for parents. |
 |
Parenting Children With Adhd: 10 Lessons That Medicine Cannot Teach (APA Lifetools) by Vincent J., Ph.D. Monastra (Author) Kids with ADHD need to be loved and shown how to become successful adults. Unfortunately, their lack of attention and restlessness often get in the way. Parents of these kids try so hard to stay connected and remain patient in the face of daily frustration. However, it is an incredible challenge to remain positive and involved when your child does not respond to the kinds of strategies that work for other children. Without guidance and systematic treatment, these bright, inquisitive children are unlikely to graduate from high school, are more prone to use illegal drugs, and struggle to maintain employment as adults. Parenting Children with ADHD: Lessons That Medicine Cannot Teach gives parents a framework for building a successful parenting program at home. Drawing from his experiences in... |
 |
Dr. Bob's Guide to Stop ADHD in 18 Days by Robert DeMaria (Author) This how-to guide can rid children and families off medications and detrimental foods - junk foods loaded with sugar, preservatives, dairy products, and trans- fattyacids - so that children and families can enjoy optimal health. "This user-friendly book has the potential of setting families free from the nightmare of ADD, ADHD, and ODD. Using drugs on kids isn't solving the problem. Follow Dr. Bob's directions and witness the change is can bring to you and your loved ones." Bruce West, D.C. Publisher, Health Alert |
 |
Taking Charge of ADHD: The Complete, Authoritative Guide for Parents (Revised Edition) by Russell A. Barkley PhD ABPP ABCN (Author) A treasured parent resource since its publication, Taking Charge of ADHD has now been revised and updated to incorporate the most current information on ADHD and its treatment. From internationally renowned ADHD expert Russell A. Barkley, the book empowers parents by arming them with the up-to-date knowledge, expert guidance, and confidence they need to ensure that their child receives the best care possible. Features of the revised edition include: *A step-by-step plan for behavior management that has helped thousands of children with ADHD *Hard data that clear up current controversies about increased diagnosis and stimulant use *New strategies that give children greater chances of success at school and in social situations *Advances in genetic and neurological research... |
 |
Learning To Slow Down & Pay Attention: A Book for Kids About Adhd by Kathleen G. Nadeau (Author), Ellen B. Dixon (Author), Charles Beyl (Author) - An APA Bestseller-over 25,000 copies sold! This book is designed as the perfect learning tool to help parents guide their child as he or she confronts the challenges of ADHD. Learning to Slow Down is unique because it is kid-centered, written from the child's point of view. This updated edition includes easy-to-read text, fun cartoons, and activities, as well as loads of self-help tips for coping with friends, family, and schoolwork, getting organized, getting disciplined, and getting things done. Appropriate for ages 6-11. Full-color illustrations. |
 |
How To Reach And Teach Children with ADD/ADHD: Practical Techniques, Strategies, and Interventions (J-B Ed: Reach and Teach) by Sandra F. Rief M.A. (Author) Sandra Rief offers myriad real-life case studies, interviews, and student intervention plans for children with ADD/ADHD. In addition, the book contains best teaching practices and countless strategies for enhancing classroom performance for all types of students. This invaluable resource offers proven suggestions for: Engaging students' attention and active participation Keeping students on-task and productive Preventing and managing behavioral problems in the classroom Differentiating instruction and addressing students' diverse learning styles Building a partnership with parents and much more. |
 |
The Gift of ADHD Activity Book: 101 Ways to Turn Your Child's Problems into Strengths (Companion) by Lara, Ph.D. Honos-Webb (Author) The chapters of the book are organized by strengths that can be developed in a child. There is a short discussion of the importance of each strength, and then the book offers simple activities that parents do with their child-often in just a few minutes-to help develop them. Throughout the book strikes a positive note, stressing things that parents can do themselves to encourage and support their child rather than things they should discourage or avoid. |
 |
Driven To Distraction : Recognizing and Coping with Attention Deficit Disorder from Childhood Through Adulthood by Edward M. Hallowell (Author), John J. Ratey (Author) Through vivid stories of the experiences of their patients (both adults and children), Drs. Hallowell and Ratey show the varied forms ADD takes -- from the hyperactive search for high stimulation to the floating inattention of daydreaming -- and the transforming impact of precise diagnosis and treatment. |
 |
ADHD & Me: What I Learned from Lighting Fires at the Dinner Table by Blake E. S. Taylor (Author) Blake Taylor's memoir, written when he was 17, offers, for the first time, a young person's account of what it's like to live and grow up with this common condition. Join Blake as he foils bullies, confronts unfair teachers, struggles with distraction and disorganization on exams, and goes sailing out-of-bounds and ends up with a boatload of spiders. It will be an inspiration and companion to the millions of others like him who must find a way to thrive with a different perspective than many of us. The book features an introduction by psychologist Lara Honos-Webb, author of The Gift of ADHD, and a leading advocate for kids with ADHD. Blake's mother first suspected he had ADHD when he, at only three years of age, tried to push his infant sister in her carrier off the... |
 |
ADHD: A Complete and Authoritative Guide (American Academy of Pediatrics) by Michael I. Reiff MD FAAP Editor-in-Chief (Editor), Sherill Tippins (Editor) This comprehensive guide to attention deficit/hyperactivity disorder (ADHD) offers parents balanced, reassuring, and authoritative information to help them understand and manage this challenging and often misunderstood condition. Based on the American Academy of Pediatrics' own clinical practice guidelines for ADHD and written in clear, accessible language, this book answers the common questions: How is ADHD diagnosed?, What are today's best treatment options, and Will my child outgrow ADHD? Accurate, up-to-date findings on evaluation and diagnosis, coexisting conditions, and unproven treatments are provided. Also addressed are behaviors associated with the teenage years and what schools can do to support children with the condition. ADHD management strategies that balance the roles of... |
| © 2009 BrightSurf.com |